此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

INCA036978 在骨髓增殖性肿瘤患者中的研究

2026年11月12日 更新者:Incyte Corporation

一项针对骨髓增殖性肿瘤患者的INCA036978的1期、开放标签、多中心研究

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

研究概览

研究类型

介入性

注册 (估计的)

218

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Incyte Corporation Call Center (US)
  • 电话号码:1.855.463.3463
  • 邮箱:medinfo@incyte.com

研究联系人备份

  • 姓名:Incyte Corporation Call Center (ex-US)
  • 电话号码:+800 00027423
  • 邮箱:eumedinfo@incyte.com

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5G 2M9
        • 招聘中
        • Princess Margaret Cancer Centre
    • Quebec
      • Montreal、Quebec、加拿大、H3T 1E2
        • 尚未招聘
        • McGill University Jewish General Hospital
      • Aachen、德国、D-52074
        • 招聘中
        • University Medical Center Rwth Aachen
      • Berlin、德国、10117
        • 招聘中
        • Charite Universitaetsmedizin Berlin - Campus Charite Mitte
      • Freiburg im Breisgau、德国、79106
        • 招聘中
        • Universitatklinikum Freiburg
      • Halle、德国、06120
        • 招聘中
        • Universitatsklinikum Halle (Saale)
      • Mainz、德国、55131
        • 尚未招聘
        • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
      • Bologna、意大利、40138
        • 尚未招聘
        • Aou Policlinico S. Orsola-Malpighi
      • Milan、意大利、20122
        • 尚未招聘
        • Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico
      • Roma、意大利、00168
        • 尚未招聘
        • A. Gemelli University Hospital, Catholic University of the Sacred Heart
      • Udine、意大利、33100
        • 尚未招聘
        • Azienda Sanitaria Universitaria Friuli Centrale Asu Fc
      • Kashiwa Chiba、日本、277-0882
        • 尚未招聘
        • National Cancer Center Hospital East
      • Toon, Ehime、日本、791-0204
        • 尚未招聘
        • Ehime University Hospital
      • Liège、比利时、04000
        • 尚未招聘
        • Centre Hospitalier Universitaire (Chu) de Liege
      • Roeselare、比利时、08800
        • 尚未招聘
        • AZ DELTA
      • Bordeaux、法国、33076
        • 招聘中
        • Francois-Xavier
      • Paris、法国、75010
        • 招聘中
        • Hospital Saint Louis
      • Villejuif、法国、94805
        • 招聘中
        • Institut Gustave Roussy
    • New South Wales
      • Concord、New South Wales、澳大利亚、02139
        • 招聘中
        • Concord General Repatriation Hospital
      • St Leonards、New South Wales、澳大利亚、02065
        • 招聘中
        • Royal North Shore Hospital
    • Queensland
      • Auchenflower、Queensland、澳大利亚、04066
        • 招聘中
        • Icon Cancer Centre
    • Victoria
      • East Melbourne、Victoria、澳大利亚、03002
        • 招聘中
        • Epworth Health Care
    • Western Australia
      • Nedlands、Western Australia、澳大利亚、06009
        • 招聘中
        • Linear Clinical Research
    • Alabama
      • Birmingham、Alabama、美国、35233
        • 尚未招聘
        • University of Alabama At Birmingham
    • California
      • Irvine、California、美国、92618
        • 招聘中
        • City of Hope-Lennar Foundation Cancer Center
      • Los Angeles、California、美国、90095
        • 尚未招聘
        • UCLA Medical Hematology & Oncology
      • Los Angeles、California、美国、90033
        • 尚未招聘
        • Usc Norris Comprehensive Cancer Center
    • Connecticut
      • New Haven、Connecticut、美国、06510
        • 尚未招聘
        • Yale Cancer Center
    • Florida
      • Miami、Florida、美国、33136
        • 尚未招聘
        • University of Miami
      • Tampa、Florida、美国、33612
        • 尚未招聘
        • Moffitt Cancer Center
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Winship Cancer Institute of Emory University
    • Maryland
      • Baltimore、Maryland、美国、21287
        • 尚未招聘
        • John Hopkins Hospital
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital
    • Missouri
      • St Louis、Missouri、美国、63108
        • 尚未招聘
        • Washington University School of Medicine
    • New York
      • New York、New York、美国、10065
        • 尚未招聘
        • Weill Cornell Medicine
      • New York、New York、美国、10029
        • 尚未招聘
        • Mount Sinai School of Medicine
      • New York、New York、美国、10021
        • 尚未招聘
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Chapel Hill、North Carolina、美国、27514
        • 招聘中
        • University of North Carolina At Chapel Hill
      • Charlotte、North Carolina、美国、28204
        • 尚未招聘
        • Levine Cancer Institute
      • Durham、North Carolina、美国、27705
        • 尚未招聘
        • Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
    • Ohio
      • Cleveland、Ohio、美国、44195
        • 尚未招聘
        • Cleveland Clinic
      • Columbus、Ohio、美国、43210
        • 招聘中
        • Ohio State University
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Tristar Bmt/Tcto
    • Texas
      • Houston、Texas、美国、77030
        • 尚未招聘
        • University of Texas M. D. Anderson Cancer Center
    • Utah
      • Salt Lake City、Utah、美国、84112
        • 尚未招聘
        • Huntsman Cancer Institute
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • 尚未招聘
        • Medical College of Wisconsin
      • London、英国、SE1 9RT
        • 尚未招聘
        • Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
      • Nottingham、英国、NG5 1PB
        • 尚未招聘
        • Nottingham University Hospitals
      • Oxford、英国、OX3 7LE
        • 招聘中
        • University of Oxford
      • Badalona、西班牙、08916
        • 尚未招聘
        • Hospital Universitari Germans Trias I Pujol
      • Las Palmas de Gran Canaria、西班牙、35010
        • 尚未招聘
        • Hospital Universitario de Gran Canaria Dr. Negrin
      • Madrid、西班牙、28041
        • 尚未招聘
        • Hospital Universitario 12 de Octubre
      • Jongno-gu, Seoul、韩国、03080
        • 尚未招聘
        • Seoul National University Hospital
      • Seocho-gu, Seoul、韩国、06591
        • 尚未招聘
        • The Catholic University of Korea Seoul St. Mary'S Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Life expectancy > 6 months.
  • Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease).
  • Participants with MF, PV and ET as defined in the protocol.

Exclusion Criteria:

  • Presence of any hematological malignancy other than MF, PV, or ET.
  • Malignancy within the last 3 years prior to enrollment.
  • Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection.
  • Clinically significant or uncontrolled cardiac disease.
  • Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
  • Laboratory values outside the Protocol-defined ranges.
  • Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment.
  • Presence of chronic or current active infectious disease requiring systemic treatment.
  • Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
  • Prior radiation therapy within 28 days before the first dose of study treatment.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1a: Dose Escalation

INCA036978 will be administered at a protocol defined starting regimen as monotherapy to identify the MTD and/or RDE(s).

INCA036978 will be administered at protocol defined dose.

实验性的:Part 1b: Dose Escalation

INCA036978 will be administered at a protocol defined starting regimen in combination with a standard disease-directed therapy to identify the MTD and/or RDE(s).

INCA036978 will be administered at protocol defined dose.

A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.

实验性的:Part 2a: Dose Expansion

INCA036978 will be administered as monotherapy at the RDE(s) identified during Part 1

INCA036978 will be administered at protocol defined dose.

实验性的:Part 2b: Dose Expansion

INCA036978 will be administered in combination with a standard disease-directed therapy at the RDE(s) identified during Part 1.

INCA036978 will be administered at protocol defined dose.

A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of participants with Dose Limiting Toxicities (DLT)s in Part 1
大体时间:Up to 28 days

Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.

Up to 28 days
Number of participants with Treatment-emergent Adverse Events (TEAEs)
大体时间:Up to approximately 2 years

Defined as adverse events AE (either reported for the first time or the worsening of a pre-existing event) occurring after the first dose of study drug and up to 60 days after last dose of study drug or until the start of a new disease-directed therapy, whichever occurs first.

Up to approximately 2 years
Number of participants with TEAEs leading to dose modification or discontinuation
大体时间:Up to approximately 2 years

Number of participants with TEAEs leading to study drug modifications (interruptions, dose reduction) or discontinuation.

Up to approximately 2 years

次要结果测量

结果测量
措施说明
大体时间
Pharmacokinetics Parameter: Cmax of INCA036978
大体时间:Up to approximately 2 years

Defined as maximum observed plasma concentration of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: Tmax of INCA036978
大体时间:Up to approximately 2 years

Defined as the time to reach the maximum plasma concentration of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: Cmax,ss of INCA036978
大体时间:Up to approximately 2 years

Defined as the maximum observed plasma concentration at steady state of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: Cmin,ss of INCA036978
大体时间:Up to approximately 2 years

Defined as the minimum observed plasma concentration at steady state of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: AUC(0-t) of INCA036978
大体时间:Up to approximately 2 years

Defined as the area under the concentration-time curve up to the last measurable concentration of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: AUC 0-∞ of INCA036978
大体时间:Up to approximately 2 years

Defined as the area under the concentration-time curve from 0 to infinity of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: CL/F of INCA036978
大体时间:Up to approximately 2 years

Defined as the apparent clearance of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: Vz/F of INCA036978
大体时间:Up to approximately 2 years

Defined as the apparent volume of distribution of INCA036978.

Up to approximately 2 years
Pharmacokinetics Parameter: t1/2 of INCA036978
大体时间:Up to approximately 2 years

Defined as the apparent terminal phase disposition half-life of INCA036978.

Up to approximately 2 years
For participants with myelofibrosis (MF): Percentage of participants achieving spleen volume reduction as defined in the protocol
大体时间:Week 12 and Week 24

Defined as percentage of participants with a protocol defined spleen volume reduction.

Week 12 and Week 24
For participants with MF and anemia: Anemia Response as defined in the protocol
大体时间:Up to approximately 2 years

For non transfusion-dependent (TD) participants: An Hb increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol.

Up to approximately 2 years
For participants with polycythemia vera (PV): Peripheral blood count remission as defined by the protocol.
大体时间:Up to approximately 2 years

Peripheral blood count remission as defined by the protocol.

Up to approximately 2 years
For participants with essential thrombocythemia (ET): Peripheral blood count remission as defined by the protocol.
大体时间:Up to approximately 2 years

Peripheral blood count remission as defined by the protocol.

Up to approximately 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Incyte Medical Monitor、Incyte Corporation

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月11日

初级完成 (估计的)

2030年5月24日

研究完成 (估计的)

2030年5月24日

研究注册日期

首次提交

2026年2月13日

首先提交符合 QC 标准的

2026年2月26日

首次发布 (实际的)

2026年3月2日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅